Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Maleic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 3/20 | 0.55 |
| ▸ | ERBB2 known ✓ | P04626 | 3/20 | 0.55 |
| ▸ | ERBB4 known ✓ | Q15303 | 3/20 | 0.55 |
| ▸ | BTK known ✓ | Q06187 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 16/20 | 0.66 |
| ▸ | SRC | P12931 | 16/20 | 0.66 |
| ▸ | TEK | Q02763 | 16/20 | 0.66 |
| ▸ | KDR | P35968 | 6/20 | 0.57 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.57 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.57 |
| ▸ | IGF1R | P08069 | 3/20 | 0.55 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.55 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.54 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL6433884 | 1.00 | LCK (0.66) | LCKSRCTEKKDRLIMK1 | |
| SCHEMBL6430369 | 0.94 | LCK (0.71) | LCKSRCTEKKDRLIMK1 | |
| SCHEMBL6430367 | 0.94 | LCK (0.71) | LCKSRCTEKKDRLIMK1 | |
| Triaziquone SCHEMBL6433881 | 0.91 | LCK (0.56) | LCKSRCTEKKDRLIMK1 | |
| SCHEMBL6430556 | 0.89 | LCK (0.82) | LCKSRCTEKKDRLIMK1 | |
| SCHEMBL6430552 | 0.89 | LCK (0.82) | LCKSRCTEKKDRLIMK1 | |
| SCHEMBL6430786 | 0.83 | EGFR (0.66) | LCKSRCTEKKDRLIMK1 | |
| SCHEMBL6430790 | 0.83 | EGFR (0.66) | LCKSRCTEKKDRLIMK1 | |
| SCHEMBL6670094 | 0.83 | LCK (0.55) | LCKSRCTEKKDRLIMK1 | |
| Acetic Acid SCHEMBL6431632 | 0.81 | SRC (0.93) | LCKSRCTEKKDRLIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | EGFR 818/4885ERBB2 894/4885ERBB4 835/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | EGFR 2229/4885ERBB2 529/4885ERBB4 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.